BOXMEER, The Netherlands and LONDON, September 26 /PRNewswire/ --     Nobilon International B.V., part of Organon, the human health care
business unit of Akzo Nobel, and Protherics PLC, the international
biopharmaceutical company focused on critical care and cancer, today
announced that Nobilon has licensed Protherics' CoVaccine HT(TM) adjuvant for
use in pandemic influenza vaccines, and seasonal influenza vaccines in
elderly people.

More than 300 million doses of seasonal influenza vaccine are produced
each year globally, leaving a considerable shortfall in the event of a
pandemic influenza outbreak. A powerful adjuvant, such as CoVaccine(TM), may
reduce the amount of antigen required in a pandemic influenza vaccine,
enabling rapid, large scale production in the event of a pandemic influenza
outbreak and for planned stockpiling. In addition, the CoVaccine HT(TM)
adjuvant may increase the potency of a seasonal influenza vaccine for elderly
people, with impaired immune systems.

The licensing agreement gives Nobilon the exclusive, global rights
excluding the US, to develop, manufacture and commercialize two new influenza
vaccines containing CoVaccine HT(TM). Protherics will receive an upfront
payment from Nobilon on signing the agreement. Protherics is also entitled to
receive success related milestone payments and royalty payments on net sales
by Nobilon.

Also announced today, Nobilon and a consortium of leading European
vaccine experts has received a EUR3.5 million grant to help fund the
development of a pandemic influenza vaccine containing CoVaccine HT(TM).

Han van den Bosch, director Research and Development of Nobilon
commented: "We are delighted to have gained exclusive access to CoVaccine HT,
a promising new adjuvant from Protherics, for use in our flu vaccines. The
very encouraging results in preclinical experiments using Nobilon's influenza
antigen produced by cell culture and Protherics' CoVaccine adjuvant,
justifies further clinical development."

Andrew Heath, Chief Executive of Protherics commented: "The agreement
with Nobilon today supports our excitement about the prospects for our
CoVaccine HT adjuvant, which we are also incorporating in our Angiotensin
Therapeutic Vaccine. We also have considerable interest from other external
parties to use our adjuvant in their vaccines across a range of other
potential indications."

About the CoVaccine HT(TM) Adjuvant

An adjuvant is a substance which enhances the immune response and so
helps maximise the production of antibodies. The CoVaccine HT(TM) adjuvant is
a sucrose fatty acid sulphate ester that increases both humoral and
cell-mediated immune responses to experimental vaccines following
intramuscular administration. In nonclinical studies, the adjuvant has been
well-tolerated with no limiting local toxicity, and has produced encouraging
immune responses.

About Nobilon

Nobilon International BV, part of Organon, a biopharmaceutical business
unit of Akzo Nobel, was founded in 2003. It has production and R&D facilities
in Boxmeer and Oss, the Netherlands. The biotechnology company is dedicated
to develop, produce and market human vaccines against infectious diseases,
building on existing expertise within sister companies Intervet and Organon.
Nobilon focuses on respiratory and traveler's diseases. One of its core
expertises is large scale cell culture production of viruses, including
influenza. Nobilon currently employs approximately 75 staff in production and
R&D. http://www.nobilon.com

About Protherics

Protherics (LSE: PTI, NASDAQ: PTIL) is a leading biopharmaceutical
company focused on the development, manufacture and marketing of specialised
products for critical care and cancer. The Company's strategy is to use the
revenues generated from its marketed and out-licensed products to help fund
the advancement of its broad, late stage pipeline. Protherics has a strong
cash position, with unaudited cash balances at 30 June 2007 of GBP45m. With
headquarters in London, the Company has approximately 270 employees across
its operations in the UK, US and Australia. For further information visit:
http://www.protherics.com

Safe Harbor Statement Organon(i)

This press release may contain statements which address such key issues
as growth strategy, future financial results, market positions, product
development, pharmaceutical products in the pipeline, and product approvals
of Organon. Such statements should be carefully considered, and it should be
understood that many factors could cause forecasted and actual results to
differ from these statements. These factors include, but are not limited to,
price fluctuations, currency fluctuations, progress of drug development,
clinical testing and regulatory approval, developments in raw material and
personnel costs, pensions, physical and environmental risks, legal issues,
and legislative, fiscal, and other regulatory measures. Stated competitive
positions are based on management estimates supported by information provided
by specialized external agencies. For a more comprehensive discussion of the
risk factors affecting our business please see our Annual Report on Form 20-F
filed with the United States Securities and Exchange Commission, a copy of
which can be found on the company's corporate website
http://www.akzonobel.com.

(i) Pursuant to the U.S. Private Securities Litigation Reform Act 1995.